CA2082804A1 - Methodes et compositions pour le traitement des affections angiogeniques - Google Patents

Methodes et compositions pour le traitement des affections angiogeniques

Info

Publication number
CA2082804A1
CA2082804A1 CA002082804A CA2082804A CA2082804A1 CA 2082804 A1 CA2082804 A1 CA 2082804A1 CA 002082804 A CA002082804 A CA 002082804A CA 2082804 A CA2082804 A CA 2082804A CA 2082804 A1 CA2082804 A1 CA 2082804A1
Authority
CA
Canada
Prior art keywords
rpf4
compound
angiostatic
compounds
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002082804A
Other languages
English (en)
Inventor
Theodore Maione
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2082804A1 publication Critical patent/CA2082804A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA002082804A 1990-07-27 1991-07-24 Methodes et compositions pour le traitement des affections angiogeniques Abandoned CA2082804A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55899990A 1990-07-27 1990-07-27
US558,999 1990-07-27

Publications (1)

Publication Number Publication Date
CA2082804A1 true CA2082804A1 (fr) 1992-01-28

Family

ID=24231872

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002082804A Abandoned CA2082804A1 (fr) 1990-07-27 1991-07-24 Methodes et compositions pour le traitement des affections angiogeniques

Country Status (4)

Country Link
EP (1) EP0541716A1 (fr)
JP (1) JPH06504262A (fr)
CA (1) CA2082804A1 (fr)
WO (1) WO1992002240A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800820A (en) * 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
US5552525A (en) * 1991-02-08 1996-09-03 Diatech Inc. Technetium-99m labeled peptides for imaging inflammation
US6019958A (en) * 1991-02-08 2000-02-01 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
AU1979392A (en) * 1991-05-14 1992-12-30 Endocon, Inc. Engineering the local inflammatory response as a means of controlled release drug delivery
EP0576669A4 (en) * 1992-01-16 1996-05-08 Repligen Corp Novel methods and compositions for treatment of angiogenic diseases
FR2691153B1 (fr) * 1992-05-18 1995-06-30 Serbio Dodecapeptides monomere et dimere, utilisation en tant qu'agents anti-megacaryocytaires.
CZ195193A3 (en) * 1992-09-25 1994-04-13 Lilly Co Eli Modified factor-4 of blood platelets, process of its preparation and pharmaceutical preparation in which it is comprised
NZ263057A (en) * 1993-03-12 2000-12-22 Xoma Corp Use of bactericidal permeability increasing proteins or derivative for treating chronic inflammatory diseases, neutralising heparin, inhibiting angiogenesis, tumour and epithelial cell proliferation
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
EA000150B1 (ru) * 1995-03-27 1998-10-29 Санофи Применение фумагиллола и его производных для приготовления лекарств, предназначенных для борьбы с кишечными инфекциями, и фармацевтическая композиция на их основе
WO1997041844A1 (fr) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinaisons de composes angiostatiques
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE69736692T2 (de) * 1996-07-16 2007-06-14 Archibald James Mixson Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie
EP1071468B1 (fr) * 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Co-administration d'un inhibiteur de l'angiogenese pour renforcer la reponse immunitaire a mediation de proteine de fusion d'une cytokine d'anticorps
ATE316982T1 (de) 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
PT1706428E (pt) 2004-01-22 2009-12-29 Merck Patent Gmbh Anticorpos anticancerígenos com fixação de complemento reduzida
US20090011981A1 (en) * 2004-09-15 2009-01-08 K.U. Leuven Research & Development Novel Inhibitors of Angiogenesis
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
ATE555125T1 (de) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases

Also Published As

Publication number Publication date
WO1992002240A2 (fr) 1992-02-20
WO1992002240A3 (fr) 1992-04-16
EP0541716A1 (fr) 1993-05-19
JPH06504262A (ja) 1994-05-19

Similar Documents

Publication Publication Date Title
US5284827A (en) Systemic treatment of metastatic cancer with platelet factor 4
CA2082804A1 (fr) Methodes et compositions pour le traitement des affections angiogeniques
KR101999756B1 (ko) Ｃｄ36 발현을 감소시키는 방법
US5112946A (en) Modified pf4 compositions and methods of use
KR101997756B1 (ko) 패혈증 예방 또는 치료용 조성물
US5759547A (en) Methods and compositions for treatment of angiogenic diseases
EP2552470B1 (fr) Peptides pour favoriser l'angiogenèse et leur utilisation
US6719969B1 (en) Treatment of liver disease and injury with CXC chemokines
NZ331757A (en) Methods of alleviating neuropathic pain using prosaposin-derived peptides the use of these peptides or fragments thereof for stimulating neurite growth, inhibiting neural cell death and promoting myelination is also described
JP2003520808A (ja) プロアポトーシス活性を有するキメラ前立腺ホーミングペプチド
US6110889A (en) Peptide tumor cell growth inhibitors
KR100580137B1 (ko) 전립선 암 치료에 유용한 접합체 및 이를 포함하는 약제학적 조성물
EP0594749A1 (fr) Compositions pf4 et procedes d'utilisation desdites compositions
CA2106368A1 (fr) Methodes et compositions pour le traitement de la maladie angiogenique
WO2001010899A2 (fr) Traitement de maladies et de lesions hepatiques avec des chimiokines cxc
WO2011119008A2 (fr) Peptides pour favoriser l'angiogenèse et leur utilisation
WO2018196743A1 (fr) Oligopeptide fonctionnel amyloïde a1 sérique humain, son procédé de préparation et son application
WO2022143938A1 (fr) Procédé d'immunothérapie antitumorale basé sur l'activation d'une cellule nk
KR20240041399A (ko) 항암 활성을 갖는 신규한 펩타이드 및 이의 용도
KR20230068866A (ko) 결핵균의 Rv3364c 단백질에서 유래한 패혈증 치료용 펩타이드
CN116139247A (zh) 一类订书肽化合物在制备治疗肺纤维化的药物中的应用
AU5762800A (en) Therapeutic peptide-based constructs
CA2178927A1 (fr) Inhibiteurs peptidiques de molecules de la famille des intercrines cxc

Legal Events

Date Code Title Description
FZDE Dead